Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

39.19 +0.73 (+1.90%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ionis Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9 Next >
A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analysts
Via Benzinga
Where Ionis Pharmaceuticals Stands With Analysts
Via Benzinga
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings)
Via Benzinga
What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
Via Benzinga
12 Analysts Have This To Say About Ionis Pharmaceuticals
Via Benzinga
The Latest Analyst Ratings For Ionis Pharmaceuticals
Via Benzinga
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
Biogen previously decided against opting into Ionis' Angelman program. 
Via Investor's Business Daily
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
Via Benzinga
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
Via Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Masters In Trading - Saturday, June 22
In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio. 
Via Talk Markets
Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year. 
Via Benzinga
Exposures Product Safety
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS. 
Via Benzinga
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes. 
Via Benzinga
The Latest Analyst Ratings For Ionis Pharmaceuticals
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals
Via Benzinga
Earnings Scheduled For February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks. 
Via InvestorPlace
IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
IONS stock results show that Ionis Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
Ionis Pharmaceuticals reports positive Phase 2 results for ION224, showing significant improvement in MASH and liver histology without worsening fibrosis. Safe and well-tolerated treatment with... 
Via Benzinga
JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval. 
Via Benzinga
Exposures Product Safety
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts
Via Benzinga
Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study
Phase 3 OASIS-HAE study results by Ionis Pharmaceuticals Donidalorsen shows remarkable efficacy, safety, and plans for FDA submission. 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.